|
|
|
|
|
HDB Compound Collections |
|
|
|
• |
Ready-to-use libraries with over 50,000 |
 |
|
compounds |
|
• |
A collection of both commercial and in- |
|
house developed unique libraries |
|
• |
Highly diversified screening tools and |
|
formats provide a greater hit probability |
|
|
|
|
|
To find a leading compound with appropriate interaction in biological models, it is a common approach to screen a drug target against a selection of chemicals. High quality compound library provides a better chance that high-throughput screening (HTS) will identify a "hit". HDB owns a combination of commercial and in-house libraries, advanced cloud-based chemo-informatics compound management system and rich experiences in |
assay development. |
|
FDA approved drug library |
- |
A unique collection of 1,370 FDA approved drugs providing an ideal research tool for |
|
new targets of old drugs |
|
|
- |
A collection of 14,400 premier compounds representing the drug-like diversity of the |
|
Maybridge screening set |
- |
Offering ready-to-use of easy & rapid lead identification |
|
|
- |
Up to 35,000 fragments with low cLogP (MW≤300 Da; cLogP≤3), allowing structural- |
|
based lead identification |
- |
Pharmacaphore rich yet simple for interpretation of the results |
|
|
- |
Dynamic growing number of compound collection synthesized via modern methodology |
- |
Novel and unique chemical space in structures not found in commercial |
- |
Hit-rich potential through HTS screenings against various targets classess |
|
|
- |
Compound management system enables smooth operation of HTS/SAR campaigns |
- |
Medicinal chemistry supports hit follow-ups, hit expansion and lead optimization |
- |
Comprehensive platforms of HTS, SAR screening, off target evaluation and drug property |
|
profiling |
- |
Outstanding track record of pharmaceutical, biotech and startup collaboration and |
|
partnership |
|
|
To receive more information on HDB compound libraries and related services, please contact us at info@hdbiosciences.com |
|
|
|
Related Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
---------------------- |
|
|
---------------------- |
|
|
|
|
|
|
|
|
|
|
|
|
|